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Alcohol can impact on both the incidence and the course of
many health conditions, and nearly 6% of all global deaths in
2012 were estimated to be attributable to its consumption.1 A
quarter of the UK adult population drinks alcohol in a way that
is potentially or actually harmful to health.2 Between 2002 and
2012 in England the number of episodes where an alcohol
related disease, injury, or condition was the primary reason for
hospital admission or a secondary diagnosis doubled.3 Despite
the large numbers of people drinking alcohol at higher risk
levels, a relatively low number access treatment.4 Possible causes
for this include missed opportunities to identify problems,
limited access to specialist services, and underdeveloped care
pathways. International studies have shown that more than 20%
of patients presenting to primary care are higher risk or
dependent drinkers,5 yet the problem of alcohol is inadequately
addressed. This review focuses on practical aspects of the
assessment and treatment of alcohol use disorders from the
perspective of the non-specialist hospital doctor or general
practitioner.
How are alcohol use disorders defined?
As the level of alcohol consumption goes up, so the risk of
physical, psychological, and social problems increases. Alcohol
related harm is a public health problem, and strategies that
reduce average consumption across the whole population by
even a small amount produce considerable health benefits.
Increasing the cost of alcohol has been consistently associated
with a reduction in alcohol related harm,6 and a minimum cost
for a unit of alcohol has been under consideration in the United
Kingdom.7
Alcoholic drinks have different strengths, and so alcohol is not
measured by number of drinks but by number of “units.” In the
United Kingdom, 1 unit comprises 8 grams of alcohol
(equivalent to 10 mL of pure ethanol), but elsewhere this value
is defined differently.8Box 1 shows how to calculate the number
of units. The terminology used to define alcohol use disorders
is currently evolving, with various organisations using slightly
different terms.9 10However, the general agreement is that there
is no such thing as a “safe level” of drinking and that the risk
of harm increases with either frequency of consumption or
amount consumed on a drinking occasion.8 To plan effective
intervention strategies, the categories of alcohol use disorders
defined in table 1⇓ are most commonly used. Figure 1⇓ shows
the prevalence of these categories in England.
The term “addiction” is not used in current classificatory
systems, partly because it has pejorative connotations. The latest
version (fifth edition) of the Diagnostic and Statistical Manual
of Mental Disorders has removed the category of dependence,
and instead describes a spectrum of alcohol use disorders of
differing severity.11 The concept of alcohol dependence is,
however, important to describe people in whom the ability to
control the frequency and extent of consumption has been
completely eroded, while recognising that dependencemay exist
at different levels of severity.12 13
How can alcohol use disorders be
identified?
Most people with risky patterns of drinking are not dependent
on alcohol (fig 1). A few minutes spent systematically
identifying drinkers at increased risk of harm and delivering
advice about moderating alcohol consumption has been shown
to be an effective strategy in various settings,14 15 and the process
of identification and brief advice should be offered as a first
step in treatment.4 In the United Kingdom, the National Institute
for Health and Care Excellence recommends that professionals
in the National Health Service should carry out alcohol screening
as part of routine practice,4 and all doctors should feel
comfortable and confident in raising the topic of alcohol
consumption in a consultation. However, the low level of
detection and treatment suggests that generalists are not
sufficiently proactive in screening groups potentially at risk,
including those who have relevant physical conditions (for
example, hypertension and gastrointestinal or liver disorders);
mental health problems, such as anxiety or depression; been
assaulted; are at risk of self harm; regularly experience
unintentional injuries or minor trauma; and regularly attend
genitourinary medicine clinics or repeatedly seek emergency
contraception.
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The bottom line
Alcohol use disorders exist across a spectrum, and public health measures to reduce the drinking of a whole population have considerable
health benefits
All front line clinicians should be aware of the potential effects of alcohol consumption and be able to screen for alcohol use disorders
using the alcohol use disorders questionnaire test
Brief interventions are quick and easy to deliver and have a potentially large impact on reducing hazardous and harmful drinking
Benzodiazepines are the drug of choice for medically assisted alcohol withdrawal
Relapse to drinking is common in the first year after stopping drinking, but psychological treatments, mutual aid groups, and relapse
prevention drugs increase the likelihood of remaining abstinent
Sources and selection criteria
We structured this review around a series of clinical guidelines developed by the UK National Institute for Health and Care Excellence. Three
separate expert groups considered public health, physical, and psychological and social issues around alcohol use. The guidance is
summarised in the form of clinical pathways (http://pathways.nice.org.uk/pathways/alcohol-use-disorders).
Box 1: How to calculate units of alcohol
The alcohol content of a drink is usually expressed by the standard measure “alcohol by volume,” or ABV. This is a measure of the
amount of pure alcohol as a percentage of the total volume of liquid in a drink and can be found on the labels of cans and bottles. For
example, if the label on a can of beer states “5% ABV” or “alcohol volume 5%,” this means that 5% of the volume of that drink is pure
alcohol.
The number of units in any drink can be calculated by multiplying the total volume of a drink (in millilitres) by its ABV (which is measured
as a percentage) and dividing the result by 1000. For example, the number of units in a pint (568 mL) of strong lager (ABV 5%) would
be calculated:
This is worth doing, as the increasing strength of many alcoholic drinks and the larger glass sizes served in bars mean that people are
often drinking more alcohol than they realise.
Units calculators are available (for example, www.nhs.uk/Tools/Pages/Alcohol-unit-calculator.aspx)
AUDIT, the alcohol use disorders identification test (fig 2⇓),
consists of 10 questions about drinking frequency and intensity,
experience of alcohol related problems, and signs of possible
dependence.16 It is the ideal screening questionnaire for detecting
drinkers at increasing or higher risk.1 Furthermore, the AUDIT
score can guide clinicians as to the best intervention, including
brief advice or a referral to specialist services (box 2). Owing
to the potentially more important effects of alcohol on certain
populations, scores should be revised downward when screening
young people aged less than 18, or adults aged more than 65
(see box 2). Biochemical measures such as liver function tests
are not normally used for screening, but may be helpful in
assessing the severity and progress of an established alcohol
related problem, or as part of a secondary care assessment.17
A guiding style that aims to build motivation and avoid
confrontation is recommended, and motivational interviewing
has shown considerable promise in this area. Although a review
is beyond the scope of this article, useful materials can be found
at www.motivationalinterviewing.org.
What treatments are available for alcohol
dependence in the non-specialist setting?
Identification and brief advice is an important public health
approach because of the numbers of people drinking at
increasing risk or higher risk levels. However, even after gold
standard brief interventions in primary care, nearly two thirds
of people will still be drinking at an increasing or higher risk
level.15At the “dependent” end of the drinking spectrum, change
is even more difficult to achieve. People with a moderate to
severe level of alcohol dependence may benefit from more
intensive help from mutual aid groups such as Alcoholics
Anonymous or specialist treatment services, or both.4Abstinence
is the preferred goal for many such people, particularly for those
whose organs have already been damaged through alcohol use,
or for those who have previously attempted to cut down their
drinking without success. In considering the correct level of
treatment intensity it is important to consider risks, capacity to
consent to treatment, the experience and outcome of previous
episodes of treatment, motivation for change, and other existing
problems, including harm to others.
Three interventionsmay assist generalists in altering the drinking
trajectory: medically assisted withdrawal, facilitation through
mutual aid, and use of drugs to prevent relapse.
Medically assisted withdrawal
The alcohol withdrawal syndrome develops when consumption
is abruptly stopped or substantially reduced, and symptoms and
signs appear within 6-8 hours. These include anxiety, tremor,
sweating, nausea, tachycardia, and hypertension, usually peaking
over 10-30 hours and subsiding within two or three days.
Seizures may occur in the first 12-48 hours (but rarely after
this), and delirium tremens is a serious condition that occurs
48-72 hours after cessation of drinking, characterised by coarse
tremor, agitation, fever, tachycardia, profound confusion,
delusions (characteristically frightening), auditory and visual
hallucinations, and possibly hyperpyrexia, ketoacidosis, and
circulatory collapse.
Minor degrees of alcohol withdrawal are common and can be
managed with information, reassurance, and adequate fluid
intake. However, the alcohol withdrawal syndrome is potentially
life threatening; systematic reviews recommend long acting
benzodiazepines (chlordiazepoxide or diazepam) as the drug of
choice for managing the alcohol withdrawal syndrome and
preventing serious complications such as seizures or delirium
tremens.19 20 The aim is to titrate the initial dose to the extent of
withdrawal symptoms and then slowly to reduce the dose over
7-10 days using a standard fixed dose protocol (table 2⇓). Rating
scales such as the clinical institute withdrawal assessment for
alcohol (CIWA-Ar) can be used to measure the severity of the
withdrawal symptoms and more accurately adjust the dose, but
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Box 2: Delivering alcohol identification and brief advice in practice
The rationale
A large body of international research evidence indicates that 1 in 8 people drinking at increasing risk or higher risk levels who receive
structured brief advice reduce their drinking to within lower risk levels.4 Raising the problem of alcohol consumption with patients often
meets with several attitudes, including indifference, confusion about what is and is not healthy, and possibly defensiveness and irritability.
Clinicians should ensure that they are aware of the facts about alcohol consumption and health related harms to convey the risks of
drinking to patients accurately. It is important to avoid stigmatising terms such as “alcoholic,” emphasising the concept of increasing risk
with increasing consumption and suggesting trying to cut down to a lower risk level rather than stopping. Clinicians should also be able
to detect alcohol dependence and refer to specialist help.
Stage 1: raise the problem
The most time and resource effective strategy in non-specialist settings is to target those at greatest risk—that is, people with relevant
physical (for example, hypertension, gastrointestinal or liver problems) or mental health (anxiety or depression) conditions, at risk of self
harm, or who regularly experience unintentional injuries or minor trauma.
Ask the first three questions on the AUDIT questionnaire (see fig 2) and score the answers (known as AUDIT-C).
Score of ≥5—suggests a high likelihood that the patient is drinking at an increasing risk level, and the full AUDIT questionnaire should
be administered (this threshold may be reduced to 3 or more in young people aged less than 18 years or adults older than 65 years)30 31
Stage 2: administer and score the 10 item AUDIT questionnaire
Score ≤7—this result should be fed back in a positive manner—for example, reiterate the sensible drinking guidelines and point out that
people who exceed these levels increase their chances of alcohol related health problems such as unintentional injuries, high blood
pressure, liver disease, cancer, and heart disease, while congratulating them for adhering to guidance
Score 8-19—this suggests that the patient’s drinking pattern is in the increasing risk or higher risk band, and clinicians should move to
offering brief advice as described in stage 3
Stage 3: deliver structured brief advice
Use an open ended “transitional” statement such as “how important is it for you to change your drinking?,” possibly accompanied by a
simple “readiness ruler”—that is, ask patients to rate between 1 and 10 how confident they feel in making changes. This can be followed
by asking what would have to happen to make the number go up.
A structured episode of brief advice may only last 5-10 minutes and is best guided by a structured advice tool (for example, www.
alcohollearningcentre.org.uk/alcoholeLearning/learning/IBA/Module4_v2/pdf/structured_advice_tool.pdf). This makes use of the FRAMES
(feedback, responsibility, advice, menu, empathy, self efficacy) structure for brief interventions. The leaflet provides material to use for
three of these elements:
• Feedback on patients’ level of drinking when compared with others, the common effects of drinking, and the potential benefits of
reduction
• A menu of options to support the attainment of their preferred drinking goal
• Advice on units and limits
Clinicians should aim to be firm enough to ensure that patients realise that it is their responsibility to make the change (restating the
need to reduce risk and encouraging patients to begin now), while also showing empathy (for example, “it can be very difficult to make
these changes if everyone around you is drinking heavily”) and aiming to boost their confidence and self efficacy (“You mentioned you
were going to drink a non-alcoholic drink first when you get home in the evening. That sounds like an excellent start. Let’s see how you
get on and arrange another time to talk to discuss how you get on”).
It is a good idea to offer a follow-up appointment to assess progress. An “extended brief intervention” places greater emphasis on
exploring the pros and cons of change and formulating a specific action plan. This approach is often based on the principles of motivational
interviewing,18 and again is best guided by a structured leaflet such as the one available at www.alcohollearningcentre.org.uk/
alcoholeLearning/learning/IBA/Module5_v2/extended_intervention_worksheet.pdf.
Patients should be referred for more specialist alcohol assessment and intervention if they ask for such help, already exhibit major
alcohol related harm, have an AUDIT score of >20, or exhibit features of the alcohol dependence syndrome.
A step by step teaching module and full range of materials is available at www.alcohollearningcentre.org.uk/eLearning/.
the use of such a regimen triggered by symptoms is only
recommended if trained staff are available, such as in an
inpatient setting.21 Prescribing in the community for alcohol
dependent patients without adequate assessment and support is
not recommended, as successful withdrawal is unlikely and
there are considerable associated clinical risks. This is a common
scenario facing general practitioners, and expeditious referral
to specialist services for support from a specialist alcohol nurse
during medicated withdrawal is advised.
Doses of benzodiazepines should be reduced for children and
young people aged less than 18 years, adults aged more than 65
years, and those with impaired liver synthetic function, such as
reduced albumin or increased prothrombin time (where a
benzodiazepine requiring less metabolismwithin the liver, such
as oxazepam, may be preferred). Clinicians should be aware of
complications from nutritional deficiency, such as the
Wernicke-Korsakoff syndrome. This should be suspected in
anyone with a history of alcohol dependence and one or more
of ophthalmoplegia, ataxia, acute confusion, memory
disturbance, or unexplained hypotension, hypothermia, or
unconsciousness. Treatment with intramuscular or intravenous
thiamine is important to prevent permanent memory loss and
should continue until the symptoms and signs stop improving.21
Most episodes of medically assisted alcohol withdrawal can
take place at home, but inpatient treatment should be considered
if patients drink more than 30 units of alcohol daily, have a
history of epilepsy, withdrawal related seizures, or delirium
tremens, or have comorbid physical or mental health
conditions.19
Mutual aid facilitation
Treatment of alcohol withdrawal is not sufficient on its own
and should be viewed as the precursor to a longer term treatment
and rehabilitation process. Research consistently shows that
people with alcohol dependence who have stopped drinking are
vulnerable to relapse and that they may have unresolved
problems that predispose them to it.22 Mutual aid groups (for
example, Alcoholics Anonymous and UK SMART Recovery)
are a source of ongoing support for people seeking recovery
from alcohol dependence, and for partners, friends, children,
and other family members. Long term cohort studies show that
people who actively participate in mutual aid are more likely
to sustain their recovery,23 and NICE recommends that treatment
staff should routinely provide information about mutual aid
groups and facilitate access for those who want to attend.19
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Clinicians should be aware of the range of mutual aid groups
available locally and how to access them. Level of clinician
knowledge about Alcoholics Anonymous groups has been
positively correlated with levels of referral,24 and attending a
meeting is an invaluable learning experience. Evidence from
randomised controlled trials suggests that proactive efforts to
engage patients with mutual aid groups increase attendance,
particularly introducing the patient to a group member in
advance of a meeting.25 A simple three stage process to guide
this is available (www.nta.nhs.uk/uploads/mutualaid-fama.pdf).
Relapse prevention drugs
Interventions based on psychological or social processes of
change are the mainstay of treatment for alcohol dependence.26
Although research suggests that such treatments lead to
improved outcomes when compared with no treatment, the
evidence favouring one type of psychological intervention over
another is less clear. Other factors such as therapist
characteristics and service variables are also important. The
uptake and implementation of psychological approaches in the
United Kingdom vary widely,19 27 and most practice involves
an eclectic approach that combines strategies from various
psychological approaches and typically lasts 12 weeks. In those
who have decided to become abstinent from alcohol, this
treatment is enhanced by both attendance at a mutual aid group
and the prescribing of relapse prevention drugs. Several drugs
can be prescribed in primary care, although they may all be
started and monitored by a specialist.
Acamprosate and the opioid antagonist naltrexone—both these
drugs are effective in increasing the time to first drink and to
relapse in people with alcohol dependence who have achieved
abstinence.19 Acamprosate may also be neuroprotective and is
believed to act by altering the balance between excitatory and
inhibitory neurotransmission.20 Naltrexone seems to reduce
cravings by reducing the reinforcing effect of alcohol
consumption. Both drugs should only be used in combination
with an individual psychological intervention, started as soon
as possible after withdrawal, and may be prescribed for six
months or more depending on perceived benefit. Systematic
reviews suggest a number needed to treat to prevent return to
any drinking of between 12 and 20.28
Disulfiram—this drug works by interfering with the metabolism
of alcohol, causing an accumulation of acetaldehyde in the body
and a throbbing headache, facial flushing, palpitations,
dyspnoea, tachycardia, nausea, and vomiting within 10minutes
of alcohol consumption. Its use as a deterrent is most suited to
people who have abstinence as a goal and who have someone
to supervise consumption each day. Treatment should be started
at least 24 hours after the last alcoholic drink and should be
used with caution in the context of pregnancy, liver disease,
severe mental illness, stroke, heart disease, or hypertension.
Patients need to know about the symptoms caused by the
interaction between alcohol and disulfiram and the rare and
unpredictable onset of hepatotoxicity, which is unrelated to
dose.
Nalmefene—is an opioid antagonist that is indicated for the
reduction of alcohol consumption in adults with alcohol
dependence who have a high risk drinking level (>7.5 units/day
in men and >5 units/day in women), but without physical
withdrawal symptoms andwho do not need immediatemedically
assisted withdrawal. The drug should be started only in patients
who continue to have a high risk drinking level two weeks after
initial assessment, and it should only be prescribed in
conjunction with continuous psychosocial support focused on
treatment adherence and reducing alcohol consumption. Such
psychosocial support can be delivered in primary care, and this
seems to be a cost effective approach to dealing with higher risk
drinking.29 The recommended dose is one tablet on each day
the patient perceives a risk of drinking, ideally 1-2 hours before
the anticipated time of drinking.
When should people with alcohol use
disorders be referred?
Referral for specialist treatment should be considered if patients
have failed to benefit from a brief intervention or an extended
brief intervention and want to receive further help, show signs
of moderate or severe alcohol dependence (see table 1), or have
severe alcohol related physical impairment or a related comorbid
condition (for example, liver disease or mental health problems).
General practitioners should actively encourage patients to
attend local mutual aid groups such as Alcoholics Anonymous,
as well as access local specialist services for full assessment
and management. The general practitioner’s role in supporting
patients and their family is crucial, as in any long term chronic
disorder.
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Tables
Table 1| Classification and definition of alcohol use disorders
AUDIT scoreDefinitionCategory of drinking
≤7No amount of alcohol consumption can be called “safe,” but risks of harm are low if consumption is below
levels specified in the “increasing risk” category (below)
Low risk
8-15Regularly drinking more than 2 or 3 units a day (women) and more than 3 or 4 units a day (men)Increasing risk (hazardous)
16-19Regularly drinking more than 6 units daily (women) or more than 8 units daily (men), or more than 35 units
weekly (women) or more than 50 units weekly (men)
Higher risk (harmful)
≥20A definite diagnosis of dependence should be made only if three or more of the following have been present
at the same time during the previous year: (a) a strong desire or sense of compulsion to drink alcohol;
difficulties in controlling drinking behaviour in terms of its onset, termination, or levels of consumption; a
physiological withdrawal state when drinking has stopped or been reduced, as evidenced by the characteristic
alcohol withdrawal syndrome, or use of the same (or a closely related) substance with the intention of relieving
or avoiding withdrawal symptoms—for example, benzodiazepines; (d) evidence of tolerance, such that
Dependence, as defined by ICD-10
(international classification of
diseases, 10th revision)9
increased quantities of alcohol are required to achieve the effects originally produced by lesser amounts; (e)
progressive neglect of alternative pleasures or interests because of alcohol consumption, increased amount
of time necessary to obtain or drink alcohol or to recover from its effects; (f) persisting with drinking alcohol
despite clear evidence of overtly harmful consequences, such as harm to the liver, depressive mood states,
or impaired cognitive functioning. It is an essential characteristic of the dependence syndrome that either
alcohol consumption or a desire to drink alcohol is present; the subjective awareness of compulsion to drink
alcohol is most commonly seen during attempts to stop or control substance use
AUDIT=alcohol use disorders identification test.
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Table 2| Suggested titrated fixed dose chlordiazepoxide protocol for treatment of alcohol withdrawal. From National Collaborating Centre
for Mental Health19
50-60 units/day30-49 units/day15-25 units/dayTreatment day
Very severe dependence:
SADQ score 40-60
Severe dependence: SADQ score 30-40Moderate dependence: SADQscore 15-25
50 mg four times/day†40 mg four times/day*30 mg four times/day25 mg four times/day15 mg four
times/day
Day 1 (starting
dose)
45 mg four times/day†35 mg four times/day*25 mg four times/day20 mg four times/day10 mg four
times/day
Day 2
40 mg four times/day*30 mg four times/day20 mg four times/day15 mg four times/day10 mg three
times/day
Day 3
35 mg four times/day*25 mg four times/day15 mg four times/day10 mg four times/day5 mg three
times/day
Day 4
30 mg four times/day20 mg four times/day10 mg four times/day10mg three times/day5 mg twice/dayDay 5
25 mg four times/day15 mg four times/day10 mg three times/day5 mg three times/day5 mg at nightDay 6
20 mg four times/day10 mg four times/day5 mg three times/day5 mg twice/day—Day 7
15 mg four times/day10 mg three times/day5 mg twice/day5 mg at night—Day 8
10 mg four times/day5 mg three times/day5 mg at night——Day 9
10 mg three times/day5 mg twice/day———Day 10
5 mg three times/day5 mg at night———Day 11
5 mg twice/day————Day 12
5 mg at night————Day 13
SADQ=severity of alcohol dependence questionnaire (www.alcohollearningcentre.org.uk/Topics/Latest/Resource/?cid=4615).
*Doses of chlordiazepoxide >30 mg four times/day should be prescribed only in severe alcohol dependence, with response to treatment monitored regularly and
closely.
†Doses of chlordiazepoxide >40 mg four times/day should be prescribed only in very severe alcohol dependence. Such doses are rarely necessary in women and
children and never in older people or in patients with liver impairment.
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Figures
Fig 1 Prevalence of alcohol use disorders in England (taken from general household survey 2009 and psychiatric morbidity
survey 2007) and recommended treatment strategies across the spectrum
Fig 2 Alcohol use disorders identification test
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